Adaptimmune Therapeutics PLC (NASDAQ:ADAP), a biotechnology company specializing in T-cell therapy to treat cancer, has entered into an amendment to its existing loan and security agreement ...

EQS-Ad-hoc: H2APEX Group SCA / Key word(s): Capital Increase/Corporate Action H2APEX Group SCA: Issuance of a Convertible Loan and a Comfort Letter ... 20,000,000 loan agreement with its ...